

ASX ANNOUNCEMENT
Tuesday, 22 October 2024

CHANGE OF BOARD

Tissue Repair Limited (ASX:TRP) (“**TRP**” or the “**Company**”) announces the appointments of Alistair McKeough and Patryk Kania as Non-Executive Directors of the Company after the close of Annual General Meeting to be held on 25 October 2024 at 10.30am.

Brief profile of new directors

Mr Kania is a medical device executive and brings over 20 years commercialisation and leadership experience in Medical Devices, Pharma, and Health Technologies, within sales and marketing management, and general management, working across the US, Europe and APAC.

Mr Kania’s commercial experience spans large public organisations and early stage start-ups. Patryk is CEO and President USA, and Managing Director of Field Orthopaedics Ltd. He has previously held senior roles at Smith+Nephew, Abbott, J&J Medical and Roche. Patryk’s knowledge of global market access, licensing arrangements, and commercialisation of medical devices will be invaluable to the Company in co-shaping its clinical, regulatory and commercial strategy. Patryk also currently serves as non-executive director of EMVision Medical Devices Ltd (ASX:EMV).

Mr McKeough is a lawyer who also has extensive experience as a director of private and listed corporations in many sectors, including professional services, corporate services, regulatory technology, sports technology, charities, education and biotech. He was formerly Head of Professional Services at Automic Group, where he led the legal and company secretarial teams. Mr McKeough is currently a non-executive director of Recce Pharmaceuticals Ltd (ASX:RCE). Mr McKeough will serve as Chair of TRP’s board.

TRP’s CEO, Tony Charara said he was pleased to welcome Alistair McKeough and Patryk Kania to the Board.

The Company further advises that Mr Jack Lowenstein, Mr Michael Silberberg and Mr Bryan Gray have resigned as directors, with effect from the close of Annual General Meeting to be held on 25 October 2024 at 10.30am.

Accordingly, Resolution 2 which relates to re-election of Mr Gray is withdrawn.

For further information in relation to this release please contact Sushma Kejriwal at s.kejriwal@acclime.com.

This announcement has been approved for release by TRP’s Board.

-ENDS-



Tissue Repair Ltd

Level 10, 255 Pitt Street, Sydney, NSW 2000
ACN: 158 411 566

About Tissue Repair

Tissue Repair Limited (ASX:TRP) is an advanced biotechnology company developing second generation wound healing agents. The Company is focusing on commencing phase 3 trials in chronic wounds for its lead drug candidate TR-987[®], with a secondary focus on commercialising TR Pro+ a post procedure topical gel to accelerate healing and improve skin quality post any cosmetic procedure. The Company's longer term strategy is to commercialise its propriety Glucoprime[®] API to treat a variety of wounds, skin and aesthetic conditions.

**Tissue Repair Ltd**

Level 10, 255 Pitt Street, Sydney, NSW 2000

ACN: 158 411 566